Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1]Ziextenzo is indicated to reduce duration of neutropenia / incidence of febrile ne…
reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment retention compared to standard of car…
Antibiotics are the cornerstone of modern medicine, but AMR represents an increasingly serious threat to global public health1Sandoz, as the world’s leading provider of high-quality antibiotics, is committed to playing a key role in efforts to balance …
Decision follows FDA request for additional information to complement submission for biosimilar rituximabSandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is already approved in EU, Switzerland, Japan and Australia Wi…
Biosimilar Hyrimoz™ (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity †Biosimilars are critical to sustaining US healthcare system, providing broader access to vital treatments for prevalent chroni…
Net sales grew 6% (cc[1], +3% USD) mainly driven by:Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indicationsEntresto more than doubled to USD 271 million (+113% cc) driven by continued uptake worldwidePromacta/Revolade US…
Net sales grew 6% (cc[1], +3% USD) mainly driven by:Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indicationsEntresto more than doubled to USD 271 million (+113% cc) driven by continued uptake worldwidePromacta/Revolade US…
Global resolution secures patient access to Sandoz biosimilar Hyrimoz® (adalimumab)[1] for the reference medicine Humira®**Resolution paves way for 2018 launch in key European markets and secures US market entry planned in 2023Holzkirchen, October 11, …
Global resolution secures patient access to Sandoz biosimilar Hyrimoz® (adalimumab)[1] for the reference medicine Humira®**Resolution paves way for 2018 launch in key European markets and secures US market entry planned in 2023Holzkirchen, October 11, …
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year’s competition expands to seek broader digital solutions to local healthcare access challen…